Japan essential medicine list and medicine supply issues: a cross-sectional study Authors: Camila Heredia, Hayase Hakariya, Akihiko Ozaki, Navindra Persaud Published: 2026 ABSTRACT ABSTRACTBackgroundEssential medicines lists aim to improve access, affordability, and quality of medicines, though their impact on pricing and supply varies. Japan’s universal coverage addresses key EML policy areas but faces drug shortages linked to generic drug promotion. This cross-sectional analysis of secondary data explores EML inclusion in the context of medicine supply issues in Japan.MethodsWe analysed Japan’s 2024 EML using data from the April 2024 Pharmaceutical Supply Survey. Unique medicines were defined by active ingredient and route. Duplicates, combinations, and non-essential categories were excluded. Supply issues were counted per medicine, but for total supply issue analysis, each medicine was counted only once.ResultsWe analysed 1107 unique medicines from Japan’s 2024 pharmaceutical supply survey. Of these, 401 (36.2%) had shipping or supply issues. Among 167 medicines listed in Japan’s 2024 EML, 80 (47.9%) had shipping issues. Most medicines with or without issues were not on the EML. A total of 847 entries described supply limitations for the 401 affected medicines. Causes included drug price deletion, quality issues, manufacturing problems, increased demand, and raw material shortages. For example, widely used essential medicines like amlodipine and metformin, not on Japan’s EML, also had reported supply issues.ConclusionsOne-third of medicines analysed had shipping issues, affecting nearly half of those on Japan’s 2024 EML. Shipping issues spanned therapeutic areas, with antibiotics most affected. This aligns with global findings linking essential medicine status and shortages, though our findings describe shipping issue patterns at a single point in time. Factors include low pricing and quality issues. Ongoing updates to the EML and a national strategy are essential to ensure availability of priority medicines.KEYWORDS: Availability, essential medicines shortage, Japan’s medicine supply, shipping issues Background Essential medicines lists (EMLs) can help promote access to medicines deemed to be needed to meet priority health needs (World Health Organization, 2023a). EMLs are supposed to be part of a national drug policy that ensures essential medicines are procured and available where they are needed (World Health Organization, 2002). While medicines are recommended to be included on EMLs after consideration of disease prevalence, public health relevance, efficacy, safety, and cost-effectiveness, other structural factors may also influence medicine inclusion on EMLs (World Health Organization, 2023b). These factors may include local production of medicines and pharmaceutical procurement processes (Kaplan et al., 2011; Peacocke et al., 2022). Including medicines in an essential medicine list may also eventually lead to price reductions (Piggott et al., 2023). In some cases, this may exacerbate supply issues if manufacturers decide for business reasons not to sell their products for a lower price (Wirtz et al., 2017). This hypothesis, though, has not been consistently verified across various contexts and healthcare settings. Japan's universal health coverage system limits out-of-pocket costs for most medical care, including medications, to 20–30% of total costs. Additionally, the system provides extra support for highly expensive drugs, based on individuals’ age and income. In this respect, while Japan does not provide extra benefits for EMLs specifically, it effectively addresses the five key domains of essential medicines policy: financing, affordability, quality and safety assurance, promoting quality use, and developing missing medicines (World Health Organization, 2023b). Japan has experienced a substantial number of drug shortages (Japanese Federation of Pharmaceutical Associations, 2024), primarily stemming from the government's aggressive promotion of generic drug use (Hashimoto et al., 2024). This policy inadvertently led to financial strain on manufacturers and potentially reduced their competitiveness (Hashimoto et al., 2024). The situation has been further complicated by a complex interplay of regulatory, economic, and quality-related challenges (Hashimoto et al., 2024). Considering these mechanisms, it is worthwhile to analyse the extent of drug shortages and compare shortage levels among medicines listed in national and international EMLs versus those not included in any EMLs. While research has often assessed shortages broadly, there are limited studies analysing EML-specific shortages, particularly within high-income countries. While there is limited data on medicine shortages in Japan more broadly, the Japan Pharmaceutical Manufacturers Association and Stability Assurance Committee has been conducting a ‘Survey on the Supply Status of Pharmaceuticals’ since 2022 (Japanese Federation of Pharmaceutical Associations, 2024). Medicine shortages are linked to several causes, including supply issues, though issues with medicine supply do not always or necessarily cause medicine shortages (Shukar et al., 2021). The purposes of this study were to conduct a cross-sectional descriptive analysis of the extent of drug supply issues in general and to determine whether medicines listed in Japan’s EML experienced supply issues at a specific point in time. Methods We included the results from the April 2024 Survey of Pharmaceutical Supply Status (Federation of Pharmaceutical Manufacturers’ Associations of Japan, April 2024) to assess shipping or supply issues and compared them with Japan’s 2024 EML (Japan 2024 EML 2024; Japanese Federation of Pharmaceutical Associations, 2024). The Survey and Japan’s EML were accessed in July 2024, and translated to English using Google Translate by the first author. The intention of the study was to capture a cross-sectional description at one time point and not assess trends or association patterns, as it was not feasible to analyse other time points. The survey includes all pharmaceuticals listed in the drug price list as of the end of April 2024, and the shipment status for each pharmaceutical was reported in an Excel document with the survey results. We identified medicines with supply issues (also referred to as shipping issues) as any that had the supply status as ‘Supply suspension’ or ‘Limited shipment’ for at least one product. We mapped reported supply issues to each unique medicine. The unit of analysis was the unique medicine defined by the active medicinal ingredient and the route of administration. Medicines with different formulations from the same manufacturer or distributor were counted only once. Combinations of two or more medicines were separated into individual medicines. Herbal formulations, contrast media, and medicines like supplements, not listed in the Global Essential Medicines database were excluded. Medicines reported with multiple supply issues were initially counted separately to distinguish the total number of medicinal products with different supply statuses. When assessing the total number of medicines with at least one supply issue, each medicine was counted only once (referred to as ‘unique medicines’) and was excluded from other categories such as normal shipping and no shipping information. We compared the prevalence of shortages between EML-listed medicines and those outside the EML and categorised reasons for supply issues (e.g. drug price deletion, quality problems, manufacturing issues, raw material shortages, demand spikes). Finally, we compared Japan’s EML to other countries to determine if medicines with supply issues in Japan at this point in time were included in the EML globally. Results We identified a total of 1107 unique medicines from the Survey of Pharmaceutical Supply Status, of which 401 (36.2%) had shipping issues, more than half (695, 62.8%) had no shipping issues, and 11 (1.0%) unique medicines had no shipping information available (Figure 1). Number of unique medicines by shipping status. Japan’s 2024 EML includes a total of 167 medicines (excluding herbal medicines, contrast media, antiseptics and disinfectants) (Japan 2024 EML 2024). Of the 167 medicines included in Japan’s 2024 EML, 80 (47.9%) had a shipping issue reported for at least one product (Table 1). Examples of medicines that are not included in Japan’s EML but were listed as having shipping issues include: amlodipine (2.5 mg tablet, listed by 134 out of 158 countries, or 84.8%, in the Global Essential Medicine database), atenolol (25 mg tablet, listed by 116 countries, or 73.4%), dexamethasone (1.65 mg in 0.5 mL injection, 0.1% ointment, and 0.5 mg tablet, listed by 150 countries, or 94.9%), fluconazole (0.1% in 50 mL, listed by 138 countries, or 87.3%), loperamide (1 mg tablet, listed by 108 countries, or 68.4%), metformin (250 mg tablet, listed by 151 countries, or 95.6%), and spironolactone (25 mg tablet, listed by 147 countries, or 93.1%). Table 1.List of the 80 medicines on Japan’s 2024 EML with reported supply issues for at least one product, as identified in the April 2024 Pharmaceutical Supply Survey.Medicine (therapeutic alternative based on ATC code, when possible) Acetylsalicylic acidHydrocortisone (dexamethasone)Acyclovir (ganciclovir)Immunoglobulins, normal humanAlbuminInterferon gammaAllergen extractsIodine productsAmikacin (gentamicin)Kanamycin (vancomycin)Amino acidsLevothyroxineAmoxicillin (ampicillin)Lidocaine/lignocaine (benzocaine)Ampicillin (bacampicillin)MagnesiumAnti-d (rh) immunoglobulinMeropenem (ertapenem)Antithrombin III (heparin)Midazolam (nitrazepam)Argatroban (dabigatran)Minocycline (doxycycline)AtropineMorphine (apomorphine)Betamethasone (hydrocortisone)Multienzymes/pancreatic enzymesCalciumMultivitaminsCarbamazepine (oxcarbazepine)Ofloxacin (ciprofloxacin)Cefaclor (cefuroxime)Omeprazole (esomeprazole)Cefalexin (cefazolin)Oxybuprocaine (tetracaine)Cefazolin (cefalotin)Paracetamol/acetaminophen (propacetamol)Cefdinir (ceftazidime)Phenobarbital/phenobarbitone (methylphenobarbital)Cefditoren (ceftazidime)Phenytoin (fosphenytoin)Cefixime (ceftazidime)Piperacillin (ampicillin)Cefmenoxime (ceftazidime)PotassiumCefoperazone (ceftazidime)Prednisolone (hydrocortisone)Ceftazidime (cefotaxime)Procaterol (salbutamol)Cefteram (ceftazidime)Propranolol (timolol)Ceftriaxone (ceftazidime)Pyrantel (oxantel)Cefuroxime (cefuroxime)Soyabean oil (glucosaminoglycan polysulfate)Chorionic gonadotrophinStreptomycin (neomycin)Clarithromycin (azithromycin)Sulbactam (tazobactam)Clindamycin (erythromycin)SulfasalazineCoagulation factor ixSultamicillin (amoxicillin-clavulanic acid)Codeine (hydrocodone)Tetanus antitoxin and immunoglobulinDalteparin (heparin)TramadolDoripenem (meropenem)Vidarabine (aciclovir)Epinephrine (phenylephrine)Vitamin a (retinol)Erythromycin (clindamycin)ZincFlomoxef (cefuroxime) Fosfomycin (linezolid) Furosemide Glycyrrhizic acid (silymarin) Gonadotropins Heparin (dalteparin) Hepatitis b immunoglobulin Hyaluronic acid List of the 80 medicines on Japan’s 2024 EML with reported supply issues for at least one product, as identified in the April 2024 Pharmaceutical Supply Survey. Of the total of 695 unique medicines with no shipping problems, the majority (616, 88.6%) were not mentioned in Japan’s 2024 EML, and 79 of those 695 (11.4%) were included. Of the total of 401 unique medicines with shipping issues, 321 (80.0%) were not mentioned in Japan’s EML, and only 80 (20.0%) were included. Of the total of 11 unique medicines with no shipping information available, 10 were not in Japan’s 2024 EML, and only one was included (human C1-inactivator concentrate). Medicines with shipping issues We identified a total of 847 medicine products within the different categories of shipping issues (representing the 401 unique medicines with shipping shortages) (Figure 2). 409 (48.3%) medicine products of the total of 847 had limited shipping because of the stop in supply, including 229 (56.0%) due to drug price deletion, 44 (10.8%) due to quality issues (including outsourced manufacturing), 32 (7.8%) due to manufacturing problems (including outsourcing), 25 (6.1%) due to problems in procuring raw materials, and 21 (5.1%) due to administrative actions (including manufacturing outsourcing), and 58 (14.2%) due to other reasons. Number of medicine products by shipping issue. Two hundred and nine (24.7%) of the 847 medicine products with shipping issues had limited shipping due to the influence of other companies’ products, with the majority (202, 96.7%) due to increased demand and only 7 (3.3%) due to drug price deletion. For the 392 unique medicines with shipping issues that were included in at least one other country’s national EML, the median number of countries listing was 42 (IQR 14–99). Twelve of these medicines were included on essential medicines lists of over 150 countries (amoxicillin, hydrocortisone, morphine, calcium, carbamazepine, iron preparations, levothyroxine, acetylsalicylic acid, metformin, dexamethasone, diazepam, and paracetamol). One hundred and seventy-eight (21%) of the total 847 medicine products had limited shipping due to company circumstances, including 72 (40.4%) due to other reasons, 56 (31.5%) due to manufacturing problems, including outsourcing, 26 (14.6%) due to problems in raw materials procurement, 16 (9%) due to quality issues, including outsourced manufacturing, 6 (3.4%) due to drug price deletion, and only 2 (1.1%) due to administrative actions (including manufacturing outsourcing). Fifty one (6%) medicine products had limited shipping because of others, most (42, 82.3%) due to increased demand, 6 (11.8%) due to other reasons, and 3 (5.9%) due to drug price deletion. Discussion One-third of the uniquely identified medicines faced shipping issues. Almost half of the unique medicines listed on Japan’s 2024 EML had shipping issues in April 2024. This indicates that medicines that meet priority health needs in Japan are at least as likely as other medicines to experience a shipping issue. The list of 80 medicines on Japan's 2024 EML that experienced shipping issues for at least one product demonstrates there are shortages across therapeutic areas. The largest number of shipping issues is seen in antibiotics, with 26 affected, followed by vitamins, minerals, and enzymes, which account for 7. Other significant categories include analgesics (total of 5), anticoagulants (total of 4), immunological agents (total of 4), and hormonal agents (total of 3). Smaller issues are noted across antivirals, corticosteroids, anaesthetics, anticonvulsants, cardiovascular agents, and local anti-inflammatory agents, among others. Our findings accord with those in other studies that focus on medicine shortages more broadly. Most medicines in shortage in China were considered essential medicines (Song et al., 2023). Lower prices for essential medicines is cited as a potential reason for shortages in Saudi Arabia (AlRuthia et al., 2023). A number of factors including problems in the quality of drugs produced in Japan have contributed to shortages (Izutsu et al., 2023). This study addresses a critical gap by examining medicine shipping issues through the lens of Japan’s EML. While global research has often assessed shortages broadly, few analyses have focused on EML-specific shortages within a high-income country. Our descriptive analysis of supply issues can be expanded to focus on medicine shortages, since supply issues have been linked to medicine shortages more broadly (Shukar et al., 2021). The national context demonstrates that even advanced healthcare systems with universal coverage are not immune to shortages of essential medicines. In our study, many medicines experienced limited distribution due to various company-related factors. These issues occur in the context of a controversial 2013 policy promoting generic drugs and reducing their price (Mamiya et al., 2024). Although we worked with the last Japan EML, it is important to keep reevaluating and updating Japan's EML based on the country's specific needs, considering that many important drugs included in other countries’ EMLs are currently absent from the Japanese list. A national strategy should then ensure that medicines on the EML are actually available as efforts are made to reduce costs. While a descriptive research study of one country cannot determine the best policy approach in any country including Japan where there are different views, our findings could help inform targeted pharmaceutical policy reforms in Japan and elsewhere when combined with other findings. To address the shipping issues we identified, Japan could implement pricing reform to address drug price deletion, and regulations to ensure compliance with Good Manufacturing Policies. Furthermore, Japan should work towards diversifying its drug supply chain to become more resilient against materials or manufacturing constraints. More upstream investments in medicine discovery will increase the number of products eligible for the Sakigake price premium (Tanaka et al., 2021). The World Health Organization (WHO) offers considerations to address medicine shortages at the national level, including building capacity to effectively negotiate medicine pricing and establishing pricing models that ensure sustainability for both health systems and industry actors (World Health Organization, 2015; World Health Organization, 2018). WHO guidance also suggests setting transparent criteria for pricing generic medicines, using mark-up regulations to incentivize supplying specific medicines such as generics and low-volume medicines, and introducing policies to maximise generic uptake (World Health Organization, 2020). Implementing and monitoring national medicine policies, including implementing and revising essential medicines, is also important to help guide procurement and set priorities for improved access and availability (Eom et al., 2016; World Health Organization, 2020). Our results can also be contextualised within broader theoretical and policy frameworks. The WHO’s essential medicines policy framework highlights five key domains – financing, affordability, quality and safety assurance, rational use, and development of missing medicines (World Health Organization, 2023b). Japan’s universal coverage system largely addresses financing and affordability, yet our results suggest an opportunity to improve in availability and quality assurance and promote rational use of medicines. Similarly, from a health systems resilience perspective, shortages represent a systemic fragility, where limited redundancy and overreliance on generic manufacturers undermine the ability to withstand shocks (Kieny et al., 2014). In the international context, shortages are increasingly framed as a regional challenge requiring collective action. The European Medicines Agency maintains a central shortages catalogue (European Medicines Agency, 2023), while the European Commission’s Pharmaceutical Strategy for Europe (European Union, 2020), and its 2023 Communication on Critical Medicines emphasise supply chain diversification, transparency, and the establishment of a Critical Medicines Alliance (European Union, 2023). WHO has also recognised the importance of harmonising what defines a medicine shortage, establishing mechanisms and standards for reporting at the global level, and developing best practices for countries to create appropriate pricing strategies, improve supply chain management, and manage shortages (World Health Organization, 2015). Grounding our analysis in these global and regional frameworks underscores that essential medicine shortages are not only market failures but also reflect policy design and governance gaps. Aligning Japan’s strategy with both WHO guidance and European initiatives could provide a pathway to strengthen resilience and secure availability of essential medicines. Our research contributes to the global essential medicines and drug shortage literature in several ways: a novel high-income country focus (this analysis shows that supply issues also significantly affect a high-income country with universal health coverage), an EML-specific lens (it provides one of the first examinations of medicine supply issues within an EML framework, quantifying that nearly half of medicines on Japan’s 2024 EML experienced supply issues), and a comparative perspective (by noting that many globally recognised essential medicines, e.g. amlodipine and metformin, are absent from Japan’s EML yet still face supply issues; the study underscores the need for alignment between global and national lists). Our findings also contribute in providing actionable insights for health policy and pharmaceutical governance for Japan and global health systems as Japan’s case illustrates that even advanced systems can be vulnerable to supply issues and potentially shortages. This preliminary descriptive analysis has several important limitations. Namely, given the availability of data in the survey, we focused our analysis on supply issues, which may cause shortages, but not necessarily so. Thus, a medicine being reported as experiencing a supply issue for at least one of its products at the analysed point in time does not necessarily mean that the medicine was in shortage. Furthermore, each medicine has many products, and so a shipping issue in one product will not necessarily affect the actual overall availability of a medicine. Shortages were measured at the level of reported shipping issues for specific products, which may not directly translate into clinical unavailability for patients, since alternative products of the same medicine may still be available. We used the 2024 edition of the Japanese EML, excluding herbal medicines and contrast media. Additionally, the dataset reflects reported supply issues at a given time point (April 2024) and may not capture all medicines or all types of shipping or supply issues that may occur. There might also be some discrepancies when comparing the Japan EML and the medicines supply issues list due to translation from Japanese to English, and potential translation inconsistencies between Japanese and English sources may have led to minor discrepancies in classification. Finally, a cross-sectional study such as this one cannot demonstrate causation. Our comparisons are descriptive and unadjusted; they do not account for utilisation volume, market concentration, or therapeutic class differences, which independently influence inclusion on EMLs and may thus confound our results, and so findings must be interpreted with caution. These limitations should be considered when interpreting our findings. Conclusion Essential medicines experience shipping or supply issues in Japan. The prevalence of shipping issues in April 2024 affecting nearly half of the unique identified medicines highlights a vulnerability in global healthcare supply chains. This indicates that even medicines deemed crucial for priority health needs are not exempt from supply disruptions. The widespread nature of these supply issues across various therapeutic areas, from antibiotics and vitamins to analgesics and immunological agents, demonstrates a systemic issue rather than isolated incidents. Japan’s experience demonstrates that essential medicine supply issues and potential shortages are not confined to low- and middle-income countries. Addressing these vulnerabilities requires coordinated national strategies focused on addressing drug price deletion, regulations to ensure compliance with Good Manufacturing Policies, and diversifying supply chains , as well as international strategies focused on diversified sourcing, strengthened manufacturing oversight, and cross-border policy alignment to safeguard the continuity of essential medicine supply worldwide. Addressing these issues and preventing future shortages is paramount for ensuring equitable access to essential medicines and maintaining robust healthcare systems. Organised approaches to addressing drug shortages could focus on essential medicines in Japan. List of abbreviations Essential medicines lists Acknowledgements CH and NP contributed to the study conceptualisation and design. HH and AO also contributed to study design. CH contributed to the data extraction. CH, HH, and AO contributed to analysis, and CH drafted the manuscript. NP contributed to the interpretation and NP, HH, and AO contributed to manuscript revision. All authors read and approved the final manuscript. Funding Statement NP was supported by funding from the Canada Research Chairs program and the Canadian Institutes of Health Research. Disclosure statement No potential conflict of interest was reported by the author(s). Availability of data and materials Survey of Pharmaceutical Supply Status (Federation of Pharmaceutical Associations, April 2024): http://www.fpmaj.gr.jp/medical-info/results-of-survey/ References Associated Data Data Availability Statement Survey of Pharmaceutical Supply Status (Federation of Pharmaceutical Associations, April 2024): http://www.fpmaj.gr.jp/medical-info/results-of-survey/